Literature DB >> 31845043

The role of melatonin in Multiple Sclerosis.

Charalampos Skarlis1, Maria Anagnostouli2,3.   

Abstract

Melatonin is a neurohormone mainly produced by the pineal gland following a circadian rhythm. It is characterized as a pleiotropic factor because it not only regulates the wake-sleep rhythm but also exerts antinociceptive, antidepressant, anxiolytic, and immunomodulating properties. Recent studies suggest that dysregulation of melatonin secretion is associated with the pathogenesis of various autoimmune diseases, such as, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and multiple sclerosis (MS). MS is an autoimmune disorder characterized by an abnormal immune response directed against the myelin sheath in the central nervous system, demyelination, oligodendrocyte death, and axonal degeneration. Recent evidence reveals that melatonin secretion is dysregulated in MS patients, suggesting that melatonin could be a potential target for therapeutic intervention. Here, we summarize the available literature regarding the role of melatonin in immune processes relevant for experimental autoimmune encephalomyelitis (EAE), MS, and the current clinical trials of melatonin supplementation in MS patients.

Entities:  

Keywords:  Autoimmunity; Experimental autoimmune encephalomyelitis (EAE); Melatonin; Multiple sclerosis (MS); Neuroimmunology; Therapeutics

Mesh:

Substances:

Year:  2019        PMID: 31845043     DOI: 10.1007/s10072-019-04137-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  138 in total

1.  Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis.

Authors:  Simone Kern; Michael Geiger; Madlen Paucke; Alina Kästner; Katja Akgün; Tjalf Ziemssen
Journal:  J Mol Med (Berl)       Date:  2019-08-30       Impact factor: 4.599

2.  Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses.

Authors:  Mauricio F Farez; Ivan D Mascanfroni; Santiago P Méndez-Huergo; Ada Yeste; Gopal Murugaiyan; Lucien P Garo; María E Balbuena Aguirre; Bonny Patel; María C Ysrraelit; Chen Zhu; Vijay K Kuchroo; Gabriel A Rabinovich; Francisco J Quintana; Jorge Correale
Journal:  Cell       Date:  2015-09-10       Impact factor: 41.582

3.  Oxidative stress induced by lipid peroxidation is related with inflammation of demyelination and neurodegeneration in multiple sclerosis.

Authors:  Pin Wang; Keqin Xie; Cunfu Wang; Jianzhong Bi
Journal:  Eur Neurol       Date:  2014       Impact factor: 1.710

4.  Decreased urinary level of melatonin as a marker of disease severity in patients with multiple sclerosis.

Authors:  Taha Gholipour; Taher Ghazizadeh; Sahand Babapour; Behzad Mansouri; Majid Ghafarpour; Bahaadin Siroos; Mohammad Hossein Harirchian
Journal:  Iran J Allergy Asthma Immunol       Date:  2015-02       Impact factor: 1.464

5.  Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS.

Authors:  F Then Bergh; T Kümpfel; C Trenkwalder; R Rupprecht; F Holsboer
Journal:  Neurology       Date:  1999-09-11       Impact factor: 9.910

Review 6.  Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 - 2014).

Authors:  Silvia Rivara; Daniele Pala; Annalida Bedini; Gilberto Spadoni
Journal:  Expert Opin Ther Pat       Date:  2015-01-12       Impact factor: 6.674

7.  Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: relationship to oxidative stress.

Authors:  Carmen Bahamonde; Cristina Conde; Eduardo Agüera; Rafael Lillo; Evelio Luque; Félix Gascón; Montserrat Feijóo; Antonio H Cruz; Fernando Sánchez-López; Isaac Túnez
Journal:  Eur J Pharmacol       Date:  2014-02-25       Impact factor: 4.432

Review 8.  Sleep Disorders in Multiple Sclerosis.

Authors:  Tiffany J Braley; Eilis Ann Boudreau
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

9.  Pinealectomy ameliorates collagen II-induced arthritis in mice.

Authors:  I Hansson; R Holmdahl; R Mattsson
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

10.  Associations of melatonin receptor gene polymorphisms with Graves' disease.

Authors:  Jiunn-Diann Lin; Shun-Fa Yang; Yuan-Hung Wang; Wen-Fang Fang; Ying-Chin Lin; Bing-Chun Liou; Yuh-Feng Lin; Kam-Tsun Tang; Chao-Wen Cheng
Journal:  PLoS One       Date:  2017-09-29       Impact factor: 3.240

View more
  5 in total

1.  First-line disease modifying treatments in pediatric-onset multiple sclerosis in Greece: therapy initiation at more advanced age is the main cause of treatment failure, in a retrospective observational study, with a cohort from a single Multiple Sclerosis Center.

Authors:  Charalampos Skarlis; Nikolaos Markoglou; Maria Gontika; Anastasia Bougea; Serafeim Katsavos; Artemios Artemiadis; George Chrousos; Marinos Dalakas; Leonidas Stefanis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2022-10-05       Impact factor: 3.830

Review 2.  Adaptive immunity, chronic inflammation and the clock.

Authors:  Kathryn J Gray; Julie E Gibbs
Journal:  Semin Immunopathol       Date:  2022-03-01       Impact factor: 11.759

Review 3.  Amino Acid Metabolism in Rheumatoid Arthritis: Friend or Foe?

Authors:  Eleonora Panfili; Roberto Gerli; Ursula Grohmann; Maria Teresa Pallotta
Journal:  Biomolecules       Date:  2020-09-04

4.  The Improved Milk Quality and Enhanced Anti-Inflammatory Effect in Acetylserotonin-O-methyltransferase (ASMT) Overexpressed Goats: An Association with the Elevated Endogenous Melatonin Production.

Authors:  Hao Wu; Xudai Cui; Shengyu Guan; Guangdong Li; Yujun Yao; Haixin Wu; Jinlong Zhang; Xiaosheng Zhang; Tuan Yu; Yunxiang Li; Zhengxing Lian; Lu Zhang; Guoshi Liu
Journal:  Molecules       Date:  2022-01-17       Impact factor: 4.411

5.  Melatonin Promotes Antler Growth by Accelerating MT1-Mediated Mesenchymal Cell Differentiation and Inhibiting VEGF-Induced Degeneration of Chondrocytes.

Authors:  Xuyang Sun; Xiaoying Gu; Keke Li; Mengqi Li; Jingna Peng; Xinxin Zhang; Liguo Yang; Jiajun Xiong
Journal:  Int J Mol Sci       Date:  2022-01-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.